Lygos: Funding, Investors & Team (Sep 2026)
Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapid optimization of pathways to convert cheap and renewable feedstock to high-value chemicals. Founded in 2011, Lygos is headquartered in Berkeley, California.
Lygos has raised $160M across 1 funding round on record, the most recent an undisclosed round of $160M announced in Apr 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Lygos Company Profile and Key Stats
Latest funding round on record: Apr 2022.
Lygos Funding Rounds
Lygos Founders and Leadership Team
Contact details for the Lygos team: 1 of 1 has an email address on file.
Start 14-day free trial →Lygos Funding Compared to Other Biotechnology Startups
Lygos' latest round of $160M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Lygos in Biotechnology and Berkeley
Companies Similar to Lygos
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Shennon Biotechnologies conducts a thorough examination and control of an enormous quantity of cells,…
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
Lygos Funding FAQs
What does Lygos do?
Lygos is providing biotechnology solutions for today’s renewable chemical challenges. They engineer microbes to convert sugars into high-value, industrial chemicals, targeting compounds where biological production is cost-advantaged over petrochemical production. The company's throughput screening and strain construction facilitate the rapid optimization of pathways to convert cheap and renewable feedstock to high-value chemicals. Founded in 2011, Lygos is headquartered in Berkeley, California.
How much funding has Lygos raised?
Lygos has raised $160M across 1 round on record. The most recent is an undisclosed round of $160M announced in Apr 2022.
When did Lygos last raise funding?
Lygos' most recent funding round on record is an undisclosed round of $160M, announced in Apr 2022.
Who is the CEO of Lygos?
Eric Steen is listed as CEO at Lygos.
Where is Lygos headquartered?
Lygos is based in Berkeley, California, United States.
How many employees does Lygos have?
Lygos is in the 11-50 employee band.
How does Lygos' funding compare to other Biotechnology startups?
Lygos' latest round of $160M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Lygos Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Lygos is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.